1 / 35

Chapter 6.

Chapter 6. Drugs acting on cardiovascular system(CVS). Part 1. Drugs Acting Ion Channels in CVS ( 作用心血管离子通道的药物). Part 2. Antiarrhythmic Drugs ( 抗心律失常药). Part 3. Drugs for Treatment of Chro-nic Cardiac Dysfunction. Part 3. Drugs for Treatment of Chro-nic Cardiac Dysfunction.

adonai
Download Presentation

Chapter 6.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter 6. Drugs acting on cardiovascular system(CVS)

  2. Part 1. Drugs Acting Ion Channels in CVS(作用心血管离子通道的药物) Part 2. Antiarrhythmic Drugs(抗心律失常药) Part 3.Drugs for Treatment of Chro-nic Cardiac Dysfunction Part 3.Drugs for Treatment of Chro-nic Cardiac Dysfunction Part 4. Antianginal Drugs(抗心绞痛药) Part 4. Antianginal Drugs(抗心绞痛药) Part 5. Antiatheroscleotic drugs(抗动脉粥样硬化药) Part 5. Antiatheroscleotic drugs(抗动脉粥样硬化药) Part 6. Antihypertensive Drugs(抗高血压药)

  3. Part 4 Antianginal Drugs (抗心绞痛药)

  4. Contents ▲Overview A.Organic nitrates B. receptor blockers C.Calcium channel blockers D. Combination of antianginal drugs

  5. ▲OVERVIEW

  6. ▲ OVERVIEW Classification of angina pectoris: (1)Stable angina pectoris: associated with sympathetic nervous system activity. (2)Unstable angina pectoris： initial onset type; accelerated type; spontaneous type. associatedwithatheroscleorsisplaque and thrombus formation. (3)Variant angina pectoris: associated with spasm of coronary arteries.

  7. ▲ OVERVIEW The causes of angina pectoris Theneed of the myocardium for oxygen. Amount deliveredfor oxygento myocar-dium by the coronary circulation.

  8. ▲ OVERVIEW Myocardial oxygen consumption is chiefly determined by: (1)Preload(venous return); (2)Afterload(arteriolar resistance); (3)Heart rate.

  9. ▲ OVERVIEW Myocardial oxygen consumption diminished by: (1)Avioding the provocative exercise; (2)Reducing the preload; (3)Reducing the afterload; (4)Reducing the heart rate.

  10. ▲ OVERVIEW Principle of antianginal drugs: (1)Dilating systemic arteries, especially coronary arteries; (2)Dilating systemic veins; (3)Anti-platelet coagulation & thrombus formation.

  11. A.Organic nitrates(硝酸酯类)

  12. A.Organic nitrates Nitroglycerin(硝酸甘油) 1. Pharmacological effects: (1)Dilating systemic vessels, and anticoaqulation of platelets; (2)Redistribution of coronary circul-ation: subendocardial area(心内膜区); epicardial vessels(心外膜血管); collateral circulation(侧枝循环);  blood supply of ischemic area.

  13. [Ca2+]i Sensitivity of contractive protein to Ca2+  cGMP  Vascular smooth muscle dilated and nticoagulation of platelets Nitroglycerin Mechanism of dilating vessels: Nitrates NO GC activated

  14. Nitroglycerin Influence of organic nitrates and dipyridamole on the blood supply of ischemic area

  15. Nitroglycerin 2. Clinical uses: (1)Angina pectoris: All types, especially stable type. (2)Heart failure. 3. Adverse effects: Symptoms due to vasodilation: headache, intraocular pressure, postural hypotension, collapse; Allergy; Methemoglobinemia; Tolerance.

  16. A.Organic nitrates Other organic nitrates(其他硝酸酯类): Isosorbide dinitrate(硝酸异山梨酯) Isosorbide mononirate(单硝酸异山梨酯) Compared with nitroglycerin: (1)Slow exertion; (2)Weaker effect; (3)Longer acting term.

  17. B. receptor blockers

  18. B. receptor blockers 1. Pharmacological effects: blocking  receptor of heart: (1)Myocardial contractility and oxygen consumption; (2)Increasing blood supply to ischemic area and increasing oxygen supply to tissues; (3)Inhibitng coagulation of platelets.

  19. B. receptor blockers 2. Therapeutic uses: stableandunstabletype, especi-ally associated with hypertension or arrhythmias, even with myocardial infarction. 3. Notices: (1)Begin with small dose; (2)Withdraw gradually(because of rebound phenomenon); (3)Had better combine with nitro-glycerin.

  20. C.Calcium channel blockers

  21. C.Calcium channel blockers 1. Pharmacological effects: (1)Decrease myocardial oxygencon-sumption; (2)Increase myocardial blood supply; (3)Protect ischemic myocardial cell; (4)Inhibit coagulation of platelets. 2. Clinical uses: (1)stable and variant type (nifedipine, verapamil, diltiazem) (2)unstable type (verapamil, diltiazem)

  22. D. Combination of antianginal drugs

  23. C. Combination of antianginal drugs

  24. C. Combination of antianginal drugs

  25. Let’s take a rest !

  26. Part 5 Antiatheroscleotic drugs (抗动脉粥样硬化药)

  27. Atherosclerosis (动脉粥样硬化)

  28. Drugs used in treatment of atheroscleosis 1. Modulating plasma lipids: ①HMG CoA reductase inhibitors: lovastatin(洛伐他汀), etc. ②Bile acid binding resins: colestryramine(考来烯胺), etc. ③Nicotinicacids:nicotinic acid(烟酸) ④Fibric acids:gemfibrozil(吉非贝齐) 2. Other drugs: ①Antioxdants:probucol(普罗布考), vit E; ②Polyenoic acids(多烯脂肪酸类); ③Protective agents for arterial endothe-lium(保护动脉内皮药).

  29. Drugs used in treatment of atheroscleosis HMG CoA reductase inhibitors 3-羟-3-甲基戊二酰辅酶A还原酶抑制剂 Lovastatin(洛伐他汀) Simvastatin(辛伐他汀) Pravastatin(普伐他汀) Fluvastatin(氟伐他汀) Mevastatin(美伐他汀) Atorvastatin(阿伐他汀) Cerivastatin(西伐他汀)

  30. (美伐他汀) (洛伐他汀) (辛伐他汀) (普伐他汀) (氟伐他汀) (阿伐他汀) (西伐他汀) HMG CoA reductase inhibitors (羟甲戊酸)

  31. (羟甲戊酸) (类异戊二烯) (角鲨烯) (胆固醇)

  32. HMG CoA reductase inhibitors 1. Pharmacological effects: (1)plasmaLDLandtotalcholesterol: toinhibit atherosclerosis forma-tion. (2)Other effects: can inhibit hypertrophy of arterial smooth muscles, inflammation, free radicals

  33. HMG CoA reductase inhibitors 2. Clinical uses: Hypercholesterolemia. to prevent cardiovascular diseases and cerebrovascular diseases. 3. Adverse effects: GI reactions Hepatotoxicity Myopathy

  34. Let’s take a rest !

More Related